RECOMBINANT HUMAN ERYTHROPOIETIN IN THE MANAGEMENT OF ANEMIA IN CHRONIC KIDNEY DISEASE (NON-DIALYSIS) PATIENTS
*Ningthoujam Bidhyarani Devi and Sohilkhan Riyazkhan Pathan
ABSTRACT
The present study was conducted to evaluate the efficacy of recombinant human erythropoietin (EPO-alpha) in the treatment of anemia in rural patients having stage-3 and stage-4 of Chronic Kidney Disease (CKD). Moreover To check the level RBCs, hemoglobin/haematocrit (markers of anaemia) and to evaluate patients on chronic kidney function tests. A descriptive observational cross-sectional study was conducted among 50 patients of anemia in chronic kidney disease in the Nephrology department of Shree Krishna Hospital, Karamsad. Cross sectional is a type of observational study that involves the analysis of data collected from the patients (before and after treatment). The present study included 50 patients as the total number of patients, out of which 18 were females and 32 were males. 92% patients had hypertension, 60% had diabetes mellitus. The average blood pressure is 138/83.68 mmHg and 73.80/min is pulse rate. After taking EPO-alpha, the hematological parameters were increased and significant clinical improvement was seen in chronic kidney disease patients. From present study, The hematological parameters (Hb, RBCs, Hct, % transferrin saturation, ferritin and TIBC) were increased and have significant clinical improvement after 3 months. Based on the results, treatment of recombinant human erythropoietin was helpful in the patients of anemia in CKD stage-3 and stage-4. They do not require blood transfusion. It shows that the role of EPO is important armamentarium for the management of anemia in CKD. In our study, we took 50 patients and all of them have CKD (non-dialysis).
Keywords: Recombinant Human Erythropoietin, chronic kidney disease, anaemia.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
